Response to Letter to Editor Regarding “Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma”
Year: 2020
Type: article
Abstract: We thank you for the opportunity to respond to the letter to the editor from Zhang et al. Large B cell lymphoma in the relapse setting has a poor prognosis because of resistance to chemotherapy. CAR T cell therapy with axicabtagene ciloleucel (axi-cel) and tisangenlecleucel (tisa-cel) have yielded high objective response rates. We presented a matching adjusted indirect comparison (MAIC) that showed higher objective response rate, complete response rate, and overall survival with axi-cel but a higher rate of grade 1-2 CRS compared with tisa-cel in patients who received infusion of the agents.
Authors: Olalekan O. Oluwole, Jeroen P. Jansen, Vincent W. Lin, Keith Chan, Sam Keeping, Lynn Navale, Frederick L. Locke
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
Funder: Kite Pharma
OpenAlex ID: W3142450396